Cooperation contract with university hospital Erlangen extended

The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2019.

The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.

It is a cooperation which takes account of the interests of all parties and therewith is advantageous for both parties.

For the ImmunoLogik it means to maintain the access to laboratories of the biosafety level 2 and 3, special equipment and especially highly qualified scientist. Particularly, the exchange among scientists and domain experts is of vital importance for the mutual success and further development of IML-106.

Therewith, the ImmunoLogik meets the expectations of its investors to conduct the upcoming work on the improvement of the bioavailability of IML-106, generation of data package about potential toxicity and confirmation of the postulated mode of action.

Image source: PublicDomainPictures –